Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Chao

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Continuing Education in the Health Professions|May 13, 2003
Peer coaching as a technique to foster professional development in clinical ambulatory settingsLeslie E Sekerka, Jason Chao
Physical Review. E|December 23, 2025
Granular potential and compactivity of jammed particlesChing Chang, Zelin Liu, Jason Chao, et al.
BMJ Case Reports|June 8, 2012
Papilloedema due to Chiari I malformationJason Chao Zhang, Belal Bakir, Andrew Lee, et al.
Diabetes Technology & Therapeutics|May 4, 2017
Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance MeasuresIldiko Lingvay, Jason Chao, Mehul R Dalal, et al.
PNAS Nexus|February 21, 2024
How persuasive is AI-generated propaganda?Josh A Goldstein, Jason Chao, Shelby Grossman, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 7, 2017
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETESMedha N Munshi, Jasvinder Gill, Jason Chao, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide aloneJennifer M Trujillo, Michelle Roberts, Terry Dex, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 6, 2018
Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-LAriel Zisman, Terry Dex, Michelle Roberts, et al.
Diabetes, Obesity & Metabolism|February 7, 2019
When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic controlGuillermo E Umpierrez, Neil Skolnik, Terry Dex, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 16, 2018
Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-LAriel Zisman, Terry Dex, Michelle Roberts, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Continuing Education in the Health Professions|May 13, 2003
Peer coaching as a technique to foster professional development in clinical ambulatory settingsLeslie E Sekerka, Jason Chao
Physical Review. E|December 23, 2025
Granular potential and compactivity of jammed particlesChing Chang, Zelin Liu, Jason Chao, et al.
BMJ Case Reports|June 8, 2012
Papilloedema due to Chiari I malformationJason Chao Zhang, Belal Bakir, Andrew Lee, et al.
Diabetes Technology & Therapeutics|May 4, 2017
Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance MeasuresIldiko Lingvay, Jason Chao, Mehul R Dalal, et al.
PNAS Nexus|February 21, 2024
How persuasive is AI-generated propaganda?Josh A Goldstein, Jason Chao, Shelby Grossman, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 7, 2017
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETESMedha N Munshi, Jasvinder Gill, Jason Chao, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide aloneJennifer M Trujillo, Michelle Roberts, Terry Dex, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 6, 2018
Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-LAriel Zisman, Terry Dex, Michelle Roberts, et al.
Diabetes, Obesity & Metabolism|February 7, 2019
When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic controlGuillermo E Umpierrez, Neil Skolnik, Terry Dex, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 16, 2018
Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-LAriel Zisman, Terry Dex, Michelle Roberts, et al.
Pageof 3